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Abstract: 
Objectives: The objective of this research was to determine the occurrence of Dyslipidemia and Microalbuminuria among those 
patients who have recently been diagnosed as Hypertensive. 
Methodology: This research was carried out at Mayo Hospital, Lahore from April 2017 to June 2018 on a total of 200 newly 
diagnosed hypertensive patients (both male and female) who were in the age bracket of 30 years to 50 years. The renal function 
test was normal among these patients (S/ Creatinine < 0.5 – 1.5 mg/dl). Patients were assessed for blood pressure, systolic pressure 
and diastolic pressure after being in a steady state for five minutes. First Krotokoff sound was considered as systolic blood pressure 
and the disappearance of the sound was considered as diastolic blood pressure. The calculation of Microalbuminuria was made 
with the estimation of Albumin within twenty-four hours of urine sample which was taken in sterilized bottles for the determination 
of Microalbuminuria occurrence among hypertensive patients. Serum Fasting lipid profile was taken after eight hours overnight 
fasting for the assessment of dyslipidemia among patients who were diagnosed or not diagnosed with Microalbuminuria. 
Results: Majority of the patients (n = 76, 38%) were in the age range of 41 years to 45 years followed by 55 patients (27.5%) in 
the age range of 46 years to 50 years. The age bracket of 36 years to 40 years included 42 patients (21%); whereas, the least 
common age bracket of 30 years to 35 years included 27 patients (13.5%). The age of the patients was in the range of 30 – 50 years 
with a mean age of (38.65 ± 3.43) years. In total research sample of 200 patients, there were 117 males (57.5%) and 83 females 
(42.5%). Microalbuminuria frequency was found among 76 newly diagnosed hypertensive patients (38%); whereas, 124 patients 
(62%) did not present an onset of microalbuminuria. We found dyslipidemia in 73 patients (36.5%). 
Conclusion: Newly diagnosed hypertensive patients presented a higher frequency of both dyslipidemia and microalbuminuria. 
Therefore, the treatment and management of both dyslipidemia and microalbuminuria are very much essential for newly developed 
hypertension among patients. 
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Systolic and Renal Function.  
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INTRODUCTION: 
Hypertension leads to an onset of cardiovascular 
diseases; its presence becomes even important in the 
presence of hyperlipidemia [1]. Normal twenty-four 
hours rate of urinary albumin excretion is twenty 
milligrams; whereas, a persistent rate from 30 to 300 
mg per day refers to an onset of microalbuminuria. 
Increased risk of microalbuminuria leads to 
cardiovascular disease risks [2]. A research outcomes 
establish that microalbuminuria was present among 
4.5% of patients having normal blood pressure, 6.3% 
among pre-hypertensive patients having blood 
pressure in the range of (120 – 139/80 – 89) mmHg, 
12.4% among first stage of hypertension with a blood 
pressure reading as (140 – 159/90 – 99) mmHg, 25.3% 
among second stage of hypertension with a blood 
pressure range of (> 160/100) mmHg and 11.3% 
among those patients who were extended hypertension 
treatment therapy [3]. However, it was 54.8% more 
than the previously reported rates [4]. 
Microalbuminuria also works as a marker as it 
indicates systemic endothelial dysfunction which is 
the initial stage of the atherosclerotic process [5, 6]. 
Essential hypertensive patients and microalbuminuria 
patients also present onset of increased thickness of 
carotid artery wall, non-fatal myocardial infarcts, left 
ventricular hypertrophy and peripheral vascular 
disease; therefore, most of the ischemic heart disease 
occurrences are reported among patients with 
microalbuminuria [7]. Annual microalbuminuria 
screening is easy and simple to perform in the light of 
international disease management guidelines which 
need to be implemented in general day to day medical 
practice [8]. 
 
Hypertension due to Dyslipidemia increases the rate of 
mortality than dyslipidemia only or hypertension only 
[9]. An author reported 27.9% of cases of 
Hypercholesterolemia among hypertension patients 
and 66.3% Hypertriglyceridemia occurrence among 
hypertensive patients [1]. Dyslipidemia is more 
common than Microalbuminuria among recently 
diagnosed hypertensive patients with a respective 
proportion of 67.7% to only 23.10%. Another author 
reported dyslipidemia as 37.5% and microalbuminuria 
as 32.3% [10]. High TC and reduced HDL-c are 
common among indication among dyslipidemia 
among hypertensive cases who also have an onset of 
microalbuminuria [10]. Microalbuminuria regression 
has an association with 27% reduced CVD risk and 
progression of Microalbuminuria has an association 
with 65% increased risk [11]. 
 
The objective of this research was to determine the 
occurrence of Dyslipidemia and Microalbuminuria 
among those patients who have recently been 
diagnosed as Hypertensive. Therefore, the patient’s 
identification by renal damage needs encouragement 
among all newly diagnosed hypertensive patients. We 
differ in dietary habits and lifestyle from other regions 
of the world so it needs different treatment. This 
research is an effort to estimate the burden of 
dyslipidemia and Microalbuminuria among 
hypertensive patients which will provide a platform 
for further studies. 
 
METHODOLOGY: 
This research was carried out at Mayo Hospital, 
Lahore from April 2017 to June 2018 on a total of 200 
newly diagnosed hypertensive patients (both male and 
female) who were in the age bracket of 30 years to 50 
years. The renal function test was normal among these 
patients as the value of S/ Creatinine was in the range 
of (< 0.5 – 1.5) mg/dl. Patients were assessed for blood 
pressure, systolic pressure and diastolic pressure after 
being in a steady state for five minutes. First Krotokoff 
sound was considered as systolic blood pressure and 
the disappearance of the sound was considered as 
diastolic blood pressure. The calculation of 
Microalbuminuria was made with the estimation of 
Albumin within twenty-four hours of urine sample 
which was taken in sterilized bottles for the 
determination of Microalbuminuria occurrence among 
hypertensive patients. Serum Fasting lipid profile was 
taken after eight hours overnight fasting for the 
assessment of dyslipidemia among patients who were 
diagnosed or not diagnosed with Microalbuminuria. 
 
RESULTS: 
Majority of the patients (n = 76, 38%) were in the age 
range of 41 years to 45 years followed by 55 patients 
(27.5%) in the age range of 46 years to 50 years. The 
age bracket of 36 years to 40 years included 42 patients 
(21%); whereas, the least common age bracket of 30 
years to 35 years included 27 patients (13.5%). The 
age of the patients was in the range of 30 – 50 years 
with a mean age of (38.65 ± 3.43) years. In total 
research sample of 200 patients, there were 117 males 
(57.5%) and 83 females (42.5%). Microalbuminuria 
frequency was found among 76 newly diagnosed 
hypertensive patients (38%); whereas, 124 patients 
(62%) did not present onset of microalbuminuria. We 
found dyslipidemia in 73 patients (36.5%). 
 
Detailed outcomes have been presented in Table – I 
(Age Distribution), Table – II (Gender Distribution 
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and Table – III (Microalbuminuria and Dyslipidemia 
(Presence and Frequency)). 
 
Table – I: Age Distribution 
 
Age Number Percentage 
30 – 35 Years 27 13.5 
36 – 40 Years 42 21 
41 – 45 Years 76 38 
46 – 50 Years 55 27.5 
Total  200 100 
Mean ± SD 38.65 ± 3.43  
 
 
 
 
Table – II: Gender Distribution 
 
Gender  Number Percentage 
Male  117 57.5 
Female  83 42.5 
Total  200 100 
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Table – III: Microalbuminuria and Dyslipidemia (Presence and Frequency) 
 
Frequency & Presence Number Percentage 
Microalbuminuria 
Yes  76 38 
No  124 62 
Dyslipidemia 
Yes  73 36.5 
No  127 63.5 
 
 
 
 
DISCUSSION: 
The most dominant age group for dyslipidemia and 
microalbuminuria was from 41 years to 45 years as 73 
patients (36.5%) had dyslipidemia and 76 patients 
(38%) had microalbuminuria. In the total population, 
there were 117 males (57.5%) and 83 females (42.5%). 
The prevalence of Microalbuminuria, as reported by 
Akinsola was less than our outcomes (38%) [12]. 
Other studies found it in the range of 4.7% to 40% [13 
– 17]. This difference may have a correlation with the 
patient’s selection process, hypertension duration, 
previous antihypertensive treatment and estimation 
method [18 – 19]. 
 
Patients having hypertension with microalbuminuria 
present a higher level of TC serum, AI and LDL 
cholesterol along with reduced HDL serum and its 
counterparts. There was a positive and significant 
association of LDL and TC serum with an onset of 
Microalbuminuria among patients; whereas, a 
negative correlation with HDL serum. It is in 
agreement with previous studies which show the 
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association of dyslipidemia and microalbuminuria 
with increased blood pressure and CVD events [20 – 
23]. Busari also reported similar outcomes as he 
reported a 37.5% rate of dyslipidemia and 32.3% rate 
of microalbuminuria [11]. 
 
There is an increased chance of microalbuminuria 
among recently diagnosed hypertensive patients along 
with dyslipidemia. This fact has also a strong 
relationship to cardiovascular events and associated 
complications. Therefore, the patient’s identification 
by renal damage needs encouragement among all 
newly diagnosed hypertensive patients. 
 
CONCLUSION: 
Newly diagnosed hypertensive patients presented a 
higher frequency of both dyslipidemia and 
microalbuminuria. Therefore, the treatment and 
management of both dyslipidemia and 
microalbuminuria are very much essential for newly 
developed hypertension among patients. 
 
REFERENCES: 
1. Rosa TT, Palatini P. Clinical value of 
microalbuminuria in hypertension. J Hypertens 
2000; 18:645-54. 
2. Bianchi S, Bigazzi R, Baldari G, Campese VM. 
Microalbuminuria in patients with essential 
hypertension: Effects of several anti-hypertensive 
drugs. Am J Med 1992; 93:525-8. 
3. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari 
G, Campese VM. Increased thickness of the 
carotid artery in patients with essential 
hypertension and microalbuminuria. J Hum 
Hypertens 1995; 9:827-33. 
4. Jensen JS. Microalbuminuria and the risk of 
atherosclerosis. Clinical epidemiology and 
physiological investigation. Dan Med Bull 2000; 
47:63-78. 
5. Biesenbach G, Zazgornik J. High prevalence of 
hypertensive retinopathy and coronary artery 
disease in patients with persistent 
microalbuminuria under short intensive anti-
hypertensive therapy. Clin Nephrol 1994; 41:211-
8. 
6. Bigazzi R, Bianchi S, Baldari D, Sgherri G, 
Baldari G, Campese VM. Microalbuminuria in 
salt sensitive patients: Marker for renal and 
cardiovascular disease. Hypertension 1994; 
23:195-9. 
7. Ahmadani MY, Fawad A, Basit A, 
Microalbuminuria prevalence study in 
hypertensive patients with type 2 diabetes in 
Pakistan, J Ayyub Med Coll 
Abbottabad2008;20(3);117-20. 
8. Hilliard LM, Russo LM and Comper WD, 
Insights into the Relationship Between 
Hypertension and Albuminuria, Current 
Hypertension Reviews, 2007;3: 29-37. 
9. Volpe M, Microalbuminuria Screening in Patients 
with Hypertension: Recommendations for 
Clinical Practice, Int J Clin Pract CME. 
2008;62(1):97-108. 
10. Kumar NL, Deepthi J, Rao YN. Study of lipid 
profile, serum magnesium and blood glucose in 
Hypertension. BioMed 2010; Vol 2 (1): 6-16. 
11. Busari OA, Opadijo OG, Olarewaju OT. 
Microalbuminuria and its relations with serum 
lipid abnormalities in adult Nigerians with newly 
diagnosed hypertension. Ann Afr Med 2010; 
9:62-7. 
12. Salles GF, Cardoso CRL, Fiszman R. Prognostic 
importance of baseline and serial changes in 
microalbuminuria in patients with resistant 
hypertension. Atherosclerosis2011;(216)1;199-
204. 
13. Akinsola A, Balogun MO, Arogundade FA, 
Olatunde LO. Microalbuminuria and it's clinical 
correlates in essential hypertension. Nig J Health 
Sci 2002; 2:25-9. 
14. Gould FG. Microalbuminuria. Association with 
height and sex in non-diabetic subjects. Br Med J 
1993;306:240-2. 
15. Derhaschnig U, Kittler H, Woisetschlger C, Bur 
A, Herkner H, Hirschl MM. Microalbuminuria 
measurement alone or calculation of 
albumin/creatinine ratio for the screening of 
hypertensive patients? Nephrol Dial Transplant 
2002; 1:81-5. 
16. Losito A, Fortunati F, Zampi I, Del Favero A. 
Impaired renal functional reserve and albuminuria 
in essential hypertension. Br Med J (Clin Res Ed) 
1988; 296:1562-4. 
17. Pedersen EB, Mogensen CE. Effects of 
antihypertensive treatment on urinary albumin 
excretion, glomerular filtration rate and renal 
plasma flow in patients with essential 
hypertension. Scand J Clin Lab Invest 1976; 
36:231-7. 
18. Bigazzi R, Bianchi S, Campese VM, Baldari G. 
Prevalence of microalbuminuria in a large 
population of patients with mild to moderate 
essential hypertension. Nephron 1992; 61:94-7. 
19. Ahmed N, Anwar W, Waqas H, Obesity, 
Hyperlipidemia, and Hyperuricemia in young and 
old hypertension patients, J Ayyub Med Coll 
Abbottabad 2009;21(4). 
IAJPS 2019, 06 (05), 10749-10754                  Mahram Hosain et al                 ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 10754 
20. Silva RP, Cisne K, Oliveira JM. Determination of 
microalbuminuria in hypertensive patients and in 
patients with coronary artery disease. Arq Bras 
Cardiol. 2008;90(2):99-103. 
21. Ogunniyi MO, Croft JB, Greenland KJ, et al. 
Racial/Ethnic Differences in Microalbuminuria 
Among Adults with Prehypertension and 
Hypertension: National Health and Nutrition 
Examination Survey (NHANES), 1999–
2006.AJH 2010; 23;859–64. 
22. Özkurt ZN, Ebinç FA, Keleş A. Frequency of 
microalbuminuria and its relationship with other 
atherosclerotic risk factors in nondiabetic 
hypertensive patients - Letter to the Editor. 
Anadolu Kardiyol Derg, 2007;7:224-6. 
23. Szántó MV, Ilyés I, Rurik I. Prevalence of 
microalbuminuria and its clinical correlation with 
other risk factors of cardiovascular diseases. Orv 
Hetil. 2010;151(35):1418-22. 
